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in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection Software for obtaining the sequencing data was MiSeq Control Software 2.6 2.1. Software for tracking the clinical samples was IRIS by 
iMedRIS.
Data analysis - Pharmacokinetics analysis was performed with Phoenix WinNonlin Build 8 (Certara). 
- Effects of antibody combination on time to viral rebound was compared to previous published data with antibody monotherapy or in 
the antibody treatment. R (version 3.4.2) with the package coin (version 1.2-2) was used for exact Wilcoxon tests in the presence of ties, 
as well as flexsurv (version 1.1) and fitdistrplus (version 1.0-9) for parametric survival regression. The weighted log-rank test was 
implemented in Matlab (version R2018a). Class probabilities were estimated with a lasso logistic regression model (Matlab function 
lassoglm) using five values for lambda and threefold cross-validation.  
- Analysis of HIV-1 envelope sequences was performed at two time points during viral suppression and at viral rebound. Nucleotide 
alignments of intact env sequences were translation-aligned using ClustalW v2.1. Maximum likelihood phylogenetic trees were then 
generated from these alignments with PhyML v3.1. Multiple alignment of nucleotide sequences guided by amino acid translations of env 
sequences was performed by TranslatorX (http://translatorx.co.uk/). Latent and rebound sequences were analyzed for the presence of 
recombination using the 3SEQ recombination algorithm (http://mol.ax/software/3seq/).  
- Levels of antibody in serum by ELISA were calculated with Softmax Pro, v5.4.5 (Molecular Devices). 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The sequences will be available in GenBank upon publication with the accession numbers MH575375-MH576416.
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All studies must disclose on these points even when the disclosure is negative.
Sample size One of the primary outcomes of the study was the percentage of participants who met ART reinitiation criteria prior to week 8. A one-sided 
upper confidence interval was constructed for the probability of meeting ART reinitiation criteria using the Clopper-Pearson method. As such, 
a sample size of 15 HIV-infected individuals would allow the rejection of the null hypothesis (rate = 0.85) with 80% power for an effect size 
equal or higher than 0.33, if at least 6 out of 15 participants enrolled in Group 2 did not experience viral rebound by week 8 (2 weeks after last 
mAb infusion). If 10 or more participants experienced viral rebound prior to week 5 [5 weeks after ART interruption and weeks after second 
3BNC117 and 10-1074 infusions], additional participants would not undergo ART interruption.
Data exclusions No data were excluded.
Replication This study was a clinical trial and the analyses were performed on individual trial participants. Experiments did not include replicates as all 
participants and data points are unique. All available data is included in the manuscript. 
Randomization The study was single arm.
Blinding The study was open label.
Reporting for specific materials, systems and methods
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Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Unique biological materials
Policy information about availability of materials
Obtaining unique materials The study included the analyses of blood samples collected from enrolled HIV-infected trial participants. These samples were 
obtained under an IRB approved protocol for the purposes of this study and associated analytical plan, therefore they cannot be 
shared without appropriate IRB review and future studies would be limited to what was covered under the original informed 
consent.
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Antibodies
Antibodies used 3BNC117 and 10-1074 are investigational anti-HIV-1 neutralizing antibodies manufactured for clinical use. They are being 
investigated under US FDA INDs 118225 and 123713. 
 
Antibodies for the Ab detection in serum by ELISA included: 
- Anti-ID 3BNC117: DHVI Protein Production Facility 
            Lot #:  3BNC 29Nov2017 
            Dilution:  4 ug/ml coating concentration 
            Clone name:  anti-ID 1F1-2E3 mAb 
- Anti-ID 10-1074:  DHVI Protein Production Facility 
            Lot #:  3Aug2016 
            Dilution:  2 ug/ml coating concentration 
            Clone name:  anti-ID 3A1-4E11 mAb 
- (HRP)-conjugated mouse anti-human IgG kappa-chain-specific antibody (Abcam),  Catalog #:  ab79115 
            Dilution:  1:15,000 
            Clone name:  SB81a
Validation 3BNC117 and 10-1074 that were administered to the participants were manufactured by Celldex Therapeutics under Good 
Manufacturing Practice and have been fully characterized in terms of biophysical properties and potency (INDs 118225 and 
123713). Both drug products are under long term stability monitoring.  
Anti-idiotypic antibodies from the Duke Human Vaccine Institute (DHVI) Protein Production facility have been validated for their 
use in ELISA against human antibodies. 
HRP-mouse monoclonal anti-human IgG kappa-chain-specific antibody has been validated for its use in ELISA and ICC/IF, 
reactivity against Human Kappa Chain. This product has been referenced in Scheid JF et al. Nature 535:556-60 (2016). 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) MOLT-4/CCR5 cell lines obtained from NIH AIDS Reagent Program, catalog number 4984. 
A stable hibridoma cell line from the Duke Protein Production Facility was utilized for the production of anti-idiotypic mAbs 
for the quantification of Ab levels in serum by ELISA.
Authentication The cells were analyzed by flow cytometry to determine the levels of CCR5 and CD4 expression.
Mycoplasma contamination The cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
Human research participants
Policy information about studies involving human research participants
Population characteristics Eligible participants were adults aged 18-65 years, HIV-1-infected, on ART for a minimum of 24 months, with plasma HIV-1 RNA 
levels of  50 copies/ml for at least 18 months (one viral blip of >50 but <500 copies/ml during this 18-month period was allowed), 
plasma HIV-1 RNA levels of  20 copies/ml at the screening visit, and a current CD4+ T cell count  500 cells/μl. 
Recruitment Participants were pre-screened for sensitivity of latent proviruses against 3BNC117 and 10-1074 antibodies by bulk PBMC viral 
outgrowth. Sensitivity was defined as an IC50 <2 μg/ml for both 3BNC117 and 10-1074 against outgrowth virus. Participants 
harboring sensitive viruses were invited for screening and were enrolled in the study sequentially. Participants were enrolled at 
two clinical sites at the Rockefeller University (New York, US) and Cologne University Hospital (Germany).
